Adrenaline is an established component of out-of-hospital cardiac arrest (OHCA) treatment, though its utility has been debated. Recently, in the PARAMEDIC-2 trial, a multicenter double-blinded placebo-controlled trial for adult OHCA in the United Kingdom, adrenaline improved rates of 30-day survival without significantly increasing the number of survivors with favorable neurologic outcomes.1 Largely driven by PARAMEDIC-2 data, an International Liaison Committee on Resuscitation (ILCOR) systematic review and meta-analysis similarly found that adrenaline significantly improved rates of return of spontaneous circulation (ROSC), survival to hospital admission, and survival to hospital discharge.
Reference:Morgan, R.W. and Berg, R.A. (2020) Intraosseous adrenaline for adult out-of-hospital cardiac arrest: Faster access with worse outcomes. Resuscitation. February 18th. doi: 10.1016/j.resuscitation.2020.02.009. (Epub ahead of print).